The allergy immunotherapy market can be segmented based on treatment type, allergen type, and end-user.
1. Sub-Segment: Subcutaneous Immunotherapy (SCIT)
Subcutaneous immunotherapy (SCIT), also known as allergy shots, involves the administration of allergen extracts through injections under the skin to desensitize the patient's immune response. SCIT is considered one of the most effective forms of allergy immunotherapy for treating severe allergic diseases, such as asthma and allergic rhinitis. The desensitization process involves gradually increasing doses of specific allergens over a period of time to build tolerance. SCIT has shown long-lasting effects and is suitable for patients who do not respond well to medication or wish to decrease their reliance on drugs.
The allergy immunotherapy market comprises several key players who are actively involved in research, development, and commercialization of innovative allergy immunotherapy products. These players utilize strategies such as collaborations, partnerships, mergers and acquisitions, and product launches to strengthen their market position. Some of the prominent players in the market include:
1. Aimmune Therapeutics Inc.
2. ALK-Abelló A/S
3. Allergy Therapeutics
4. DBV Technologies
5. HAL Allergy Group
6. Merck & Co., Inc.
7. Stallergenes Greer plc
8. Allergopharma (Merck KGaA)
9. Biomay AG
10. Circassia
These market players focus on offering a diverse range of allergy immunotherapy products and constantly strive to enhance their product portfolio through extensive research and development activities.